TGFβ secreted by B16 melanoma antagonizes cancer gene immunotherapy bystander effect

Cancer Immunology, Immunotherapy

Volumn 57, Issue 8, 2008, Pages 1197-1206

  Penafuerte, Claudia ^a   Galipeau, Jacques ^b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

B16 melanoma; Bystander effect; Gene therapy; Immunology; TGF

Indexed keywords

CYTOKINE ANTIBODY; FUSOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR BETA; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; BYSTANDER EFFECT; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CELL COUNT; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENETIC ENGINEERING; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; MELANOMA B16; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; TUMOR IMMUNITY;

ANIMALS; BYSTANDER EFFECT; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DOWN-REGULATION; FEMALE; GENE THERAPY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; IMMUNOTHERAPY; INTERFERON TYPE II; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR BETA SUBUNIT; KILLER CELLS, NATURAL; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; TRANSFORMING GROWTH FACTOR BETA;

EID: 44249100929     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-008-0453-1     Document Type: Article

References (24)

1. Arteaga CL, Dugger TC, Winnier AR, Forbes JT (1993) Evidence for a positive role of transforming growth factor-beta in human breast cancer cell tumorigenesis 6. J Cell Biochem Suppl 17G:187-193
2. Arteaga CL, Hurd SD, Winnier AR, Johnson MD, Fendly BM, Forbes JT (1993) Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression 1. J Clin Invest 92:2569-2576
3. Bouzahzah B, Fu M, Iavarone A, Factor VM, Thorgeirsson SS, Pestell RG (2000) Transforming growth factor-beta1 recruits histone deacetylase 1 to a p130 repressor complex in transgenic mice in vivo. Cancer Res 60:4531-4537
4. Cho CH, Lee BK, Kwak SM, Kim JD (1999) Monophosphoryl lipid A (MPL) upregulates major histocompatibility complex (MHC) class I expression by increasing interferon-gamma (IFN-gamma). Yonsei Med J 40(1):20-25
5. Dranoff G, Jaffee E, Lazenby A, et al. (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90:3539-3543
6. Fidler IJ (1975) Biological behavior of malignant melanoma cells correlated to their survival in vivo. Cancer Res 35(1):218-224
7. Fidler IJ, Bucana C (1977) Mechanism of tumor cell resistance to lysis by syngeneic lymphocytes. Cancer Res 37(11):3945-3956
8. Inge TH, McCoy KM, Susskind BM, Barrett SK, Zhao G, Bear HD (1992) Immunomodulatory effects of transforming growth factor-beta on T lymphocytes. Induction of CD8 expression in the CTLL-2 cell line and in normal thymocytes 1. J Immunol 148:3847-3856
9. Khammari A, Nguyen JM, Pandolfino MC, et al. (2007) Long term follow-up of patients treated by adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunol Immunother 56:1853-1860
10. Koli K, Saharinen J, Hyytiainen M, Penttinen C, Keski-Oja J (2001) Latency, activation, and binding proteins of TGF-beta. Microsc Res Tech 52:354-362
11. McKarns SC, Letterio JJ, Kaminski NE (2003) Concentration-dependent bifunctional effect of TGF-beta 1 on immunoglobulin production: a role for Smad3 in IgA production in vitro. Int Immunopharmacol 3:1761-1774
12. Medrano EE (2003) Repression of TGF-beta signaling by the oncogenic protein SKI in human melanomas: consequences for proliferation, survival, and metastasis. Oncogene 22:3123-3129
13. Meunier MC, Delisle JS, Bergeron J, Rineau V, Baron C, Perreault C (2005) T cells targeted against a single minor histocompatibility antigen can cure solid tumors 1. Nat Med 11:1222-1229
14. Nelson BH, Martyak TP, Thompson LJ, Moon JJ, Wang T (2003) Uncoupling of promitogenic and antiapoptotic functions of IL-2 by Smad-dependent TGF-beta signaling. J Immunol 170:5563-5570
15. Pardoll DM (1993) New strategies for enhancing the immunogenicity of tumors. Curr Opin Immunol 5:719-725
16. Pawelec G (2004) Immunotherapy and immunoselection - tumour escape as the final hurdle. FEBS Lett 567:63-66
17. Petritsch C, Beug H, Balmain A, Oft M (2000) TGF-beta inhibits p70 S6 kinase via protein phosphatase 2A to induce G (1) arrest. Genes Dev 14:3093-3101
18. Rodeck U, Bossler A, Graeven U, Fox FE, Nowell PC, Knabbe C, Kari C (1994) Transforming growth factor beta production and responsiveness in normal human melanocytes and melanoma cells. Cancer Res 54(2):575-581
19. Rosenberg SA (2001) Progress in human tumour immunology and immunotherapy. Nature 411(6835):380-384
20. Sotomayor MG, Yu H, Antonia S, Sotomayor EM, Pardoll DM (2002) Advances in gene therapy for malignant melanoma 1. Cancer Control 9:39-48
21. Stagg J, Wu JH, Bouganim N, Galipeau J (2004) Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy. Cancer Res 64:8795-8799
22. Suzuki H, Duncan GS, Takimoto H, Mak TW (1997) Abnormal development of intestinal intraepithelial lymphocytes and peripheral natural killer cells in mice lacking the IL-2 receptor beta chain 3. J Exp Med 185:499-505
23. Ulloa L, Doody J, Massague J (1999) Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway 8. Nature 397:710-173
24. Umehara H, Bloom ET (1990) The IL-2 receptor beta subunit is absolutely required for mediating the IL-2-induced activation of NK activity and proliferative activity of human large granular lymphocytes. Immunology 70(1):111-115